Get the Stockscreener App
0.93
1.55%
0.0142
After Hours:
.90
-0.03
-3.23%
Cytosorbents Corp stock is traded at $0.93, with a volume of 37,668.
It is up +1.55% in the last 24 hours and down -0.91% over the past month.
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
See More
Previous Close:
$0.9158
Open:
$0.92
24h Volume:
37,668
Relative Volume:
0.23
Market Cap:
$58.37M
Revenue:
$33.79M
Net Income/Loss:
$-18.67M
P/E Ratio:
-2.5963
EPS:
-0.3582
Net Cash Flow:
$-19.17M
1W Performance:
-1.06%
1M Performance:
-0.91%
6M Performance:
-4.32%
1Y Performance:
-16.96%
1-Day Range:
$0.92
$0.9857
1-Week Range:
$0.90
$0.9999
52-Week Range:
$0.7101
$1.61
Cytosorbents Corp Stock (CTSO) Company Profile
Name
Cytosorbents Corp
Sector
Industry
Phone
973-329-8885
Address
305 COLLEGE ROAD EAST, PRINCETON, NJ
Compare CTSO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTSO
Cytosorbents Corp
|
0.93 | 57.48M | 33.79M | -18.67M | -19.17M | -0.3582 |
|
ABT
Abbott Laboratories
|
131.38 | 230.73B | 43.11B | 13.94B | 6.78B | 7.9963 |
|
BSX
Boston Scientific Corp
|
94.95 | 141.37B | 18.49B | 2.50B | 3.49B | 1.6801 |
|
SYK
Stryker Corp
|
364.92 | 139.39B | 23.82B | 2.92B | 4.02B | 7.5574 |
|
MDT
Medtronic Plc
|
95.58 | 122.43B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
72.95 | 43.41B | 5.69B | 1.41B | 577.90M | 6.9828 |
Cytosorbents Corp Stock (CTSO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-07-23 | Initiated | B. Riley Securities | Buy |
| Oct-14-21 | Resumed | B. Riley Securities | Buy |
| Sep-17-20 | Initiated | Jefferies | Buy |
| Sep-01-20 | Initiated | SVB Leerink | Outperform |
| Aug-08-17 | Reiterated | Maxim Group | Buy |
| Oct-26-16 | Initiated | Aegis Capital | Buy |
| May-24-16 | Initiated | Maxim Group | Buy |
| Oct-29-15 | Upgrade | WBB Securities | Speculative Buy → Buy |
| May-12-15 | Reiterated | MLV & Co | Buy |
| Apr-01-15 | Reiterated | MLV & Co | Buy |
| Mar-05-15 | Initiated | MLV & Co | Buy |
| Feb-25-15 | Initiated | WBB Securities | Speculative Buy |
| Jan-27-15 | Reiterated | H.C. Wainwright | Buy |
View All
Cytosorbents Corp Stock (CTSO) Latest News
Using economic indicators to assess Cytosorbents Corporation potential2025 AllTime Highs & Free Daily Entry Point Trade Alerts - newser.com
Using data tools to time your Cytosorbents Corporation exitWeekly Market Report & Weekly Consistent Profit Watchlists - newser.com
Will Cytosorbents Corporation (HQE1) stock beat value stocksDividend Hike & Consistent Profit Trading Strategies - newser.com
What is the fair value estimate for Cytosorbents Corporation (HQE1) stock in 2025IPO Watch & Accurate Technical Buy Alerts - newser.com
Cytosorbents Faces Nasdaq Non-Compliance Notice - MSN
Published on: 2025-10-06 01:54:06 - newser.com
Is Cytosorbents Corporation (HQE1) stock vulnerable to rate hikesJuly 2025 EndofMonth & Intraday High Probability Alerts - newser.com
Published on: 2025-10-06 00:49:59 - newser.com
What machine learning models say about Cytosorbents CorporationQuarterly Portfolio Review & Risk Controlled Daily Trade Plans - newser.com
Custom watchlist performance reports with Cytosorbents CorporationWeekly Profit Analysis & Fast Entry and Exit Trade Plans - newser.com
Why retail traders accumulate Cytosorbents Corporation (HQE1) stockWeekly Profit Analysis & Growth Focused Investment Plans - newser.com
Can Cytosorbents Corporation stock beat market expectations this quarterBear Alert & Fast Gain Swing Alerts - newser.com
Is Cytosorbents Corporation (HQE1) stock worth buying before Fed actionJuly 2025 Big Picture & AI Based Buy/Sell Signal Reports - newser.com
Cytosorbents receives Nasdaq notice for non-compliance with minimum bid price - Investing.com
Is Cytosorbents Corporation forming a bottoming base2025 Buyback Activity & Free Safe Capital Growth Stock Tips - newser.com
Is it time to cut losses on Cytosorbents CorporationWeekly Profit Analysis & High Conviction Buy Zone Alerts - newser.com
Order flow analysis tools used on Cytosorbents CorporationWeekly Trade Report & Low Risk Investment Opportunities - newser.com
Cytosorbents Corporation $CTSO Shares Bought by Goldman Sachs Group Inc. - Defense World
Does Cytosorbents Corporation show high probability of reboundTrade Risk Summary & Real-Time Chart Pattern Alerts - newser.com
CytoSorbents to Showcase Pioneering New Cardiac Surgery Data in Key Applications at the EACTS 2025 Annual Meeting in Copenhagen - Eastern Progress
Why Cytosorbents Corporation (HQE1) stock is trending on social media2025 Top Decliners & AI Optimized Trading Strategy Guides - newser.com
Is Cytosorbents Corporation building a consolidation base2025 Short Interest & Stock Market Timing Techniques - newser.com
Can Cytosorbents Corporation (HQE1) stock survive global slowdown2025 Pullback Review & AI Driven Price Forecasts - newser.com
First Randomized Trial Data: CytoSorbents' DrugSorb-ATR Shows Success in Urgent Cardiac Surgery Safety - Stock Titan
Published on: 2025-09-27 14:19:40 - newser.com
Cytosorbents Corporation stock trend forecastJuly 2025 Retail & Fast Entry High Yield Tips - newser.com
Published on: 2025-09-25 10:35:40 - newser.com
Cytosorbents Corp Stock (CTSO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cytosorbents Corp Stock (CTSO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MARIANI PETER J | Chief Financial Officer |
Dec 13 '24 |
Buy |
0.96 |
20,000 |
19,294 |
401,363 |
| MARIANI PETER J | Chief Financial Officer |
Dec 12 '24 |
Buy |
0.89 |
20,000 |
17,872 |
381,363 |
| MARIANI PETER J | Chief Financial Officer |
Dec 11 '24 |
Buy |
0.89 |
11,363 |
10,103 |
361,363 |
0.01%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):